(Q39128566)

9 September 2017

title

Chikungunya Virus Vaccines: Viral Vector-Based Approaches (English)

1 reference

9 September 2017

0 references

1 reference

1 reference

2

Frédéric Tangy

1 reference

9 September 2017

Katrin Ramsauer

1

1 reference

9 September 2017

language of work or name

English

0 references

publication date

1 December 2016

1 reference

Journal of Infectious Diseases

9 September 2017

published in

1 reference

9 September 2017

volume

214

1 reference

9 September 2017

issue

suppl 5

1 reference

9 September 2017

page(s)

S500-S505

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW369

9 September 2017

1 reference

Chikungunya virus-associated long-term arthralgia: a 36-month prospective longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW369

Chikungunya virus and prospects for a vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW369

Multiple immune factors are involved in controlling acute and chronic chikungunya virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW369

Genetic divergence of Chikungunya viruses in India (1963-2006) with special reference to the 2005-2006 explosive epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW369

Developments in Viral Vector-Based Vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW369

Innate immune recognition of DNA: A recent history

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW369

RIG-I in RNA virus recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW369

Immunologic basis of vaccine vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW369

Pre-existing immunity against vaccine vectors--friend or foe?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW369

Effect of preexisting immunity on an adenovirus vaccine vector: in vitro neutralization assays fail to predict inhibition by antiviral antibody in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW369

Pre-existing adenovirus immunity modifies a complex mixed Th1 and Th2 cytokine response to an Ad5/HIV-1 vaccine candidate in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW369

Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW369

Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW369

Prime-boost immunization strategies against Chikungunya virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW369

A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW369

Chimeric alphavirus vaccine candidates for chikungunya

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW369

Conservation of a packaging signal and the viral genome RNA packaging mechanism in alphavirus evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW369

Chimeric Chikungunya viruses are nonpathogenic in highly sensitive mouse models but efficiently induce a protective immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW369

Recombinant modified vaccinia virus Ankara expressing glycoprotein E2 of Chikungunya virus protects AG129 mice against lethal challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW369

A novel MVA vectored Chikungunya virus vaccine elicits protective immunity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW369

A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW369

A chimeric vesiculo/alphavirus is an effective alphavirus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW369

Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW369

A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW369

Oncolytic measles virus strains as novel anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW369

Live attenuated measles vaccine as a potential multivalent pediatric vaccination vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW369

A molecularly cloned Schwarz strain of measles virus vaccine induces strong immune responses in macaques and transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW369

Measles vaccine expressing the secreted form of West Nile virus envelope glycoprotein induces protective immunity in squirrel monkeys, a new model of West Nile virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW369

Pediatric measles vaccine expressing a dengue tetravalent antigen elicits neutralizing antibodies against all four dengue viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW369

Immunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW369

Immunogenicity of a recombinant measles HIV-1 subtype C vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW369

Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW369

Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW369

Alphavirus-based vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW369

Chimeric Sindbis/eastern equine encephalitis vaccine candidates are highly attenuated and immunogenic in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW369

Transmission potential of two chimeric Chikungunya vaccine candidates in the urban mosquito vectors, Aedes aegypti and Ae. albopictus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW369

Extended Preclinical Safety, Efficacy and Stability Testing of a Live-attenuated Chikungunya Vaccine Candidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW369

Adenovirus vectors for gene therapy, vaccination and cancer gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW369

A complex adenovirus vaccine against chikungunya virus provides complete protection against viraemia and arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW369

Chikungunya virus arthritis in adult wild-type mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW369

Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW369

Differences in virus-induced cell morphology and in virus maturation between MVA and other strains (WR, Ankara, and NYCBH) of vaccinia virus in infected human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW369

Utilizing poxviral vectored vaccines for antibody induction-progress and prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW369

Longitudinal analysis of the human antibody response to Chikungunya virus infection: implications for serodiagnosis and vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW369

The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW369

Rescue of measles viruses from cloned DNA.

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27920181

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Immunity's yin and yang. A successful vaccine must first avoid being eliminated by pre-existing immunity before it can promote a protective immune response

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27920181

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Vaccinia virus DNA replication occurs in endoplasmic reticulum-enclosed cytoplasmic mini-nuclei

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27920181

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1093/INFDIS/JIW369

1 reference

9 September 2017

0 references

1 reference